Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Publication Type:

Journal Article


The Lancet. Oncology, Volume 16, Issue 2, p.152-60 (2015)


Aged, Androstenes, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, DISEASE PROGRESSION, Double-Blind Method, Follow-Up Studies, Humans, Male, Neoplasm Staging, Prednisone, Prognosis, Prostatic Neoplasms, Castration-Resistant, Survival Rate


Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.